Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model.
Michael Ruberson Ribeiro da SilvaJéssica Barreto Ribeiro Dos SantosAlessandra Maciel AlmeidaJuliana Alvares-TeodoroFrancisco de Assis AcurcioPublished in: Expert review of pharmacoeconomics & outcomes research (2021)
The difference between the drugs in terms of utility was minimal and the costs were the main factor that impacted the cost-utility ratio, which points to the benefits of price renegotiation for the efficient allocation of resources in the health system.